Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oragenics has been selected to receive a $0.5 million grant to advance development of its unique small peptide antibiotic synthesis program using the company's proprietary Differentially Protected Orthogonal Lanthionine Technology or DPOLT.
Subscribe to our email newsletter
This two-year Phase II grant, awarded through the Small Business Innovation Research (SBIR) program of the National Science Foundation, will support studies focused on the synthesis and testing of the company’s lead antibiotic, MU1140. Successful development of DPOLT will enable, for the first time, large-scale commercial production of MU1140 and other related antibiotics, which the company believes will be effective in treating some of the most troublesome human infections.